E-news: Testosterone replacement therapy for older men may not be a panacea after all

Basaria et al have reported an increase risk of cardiovascular events in men over 65 treated with testosterone replacement therapy.

This randomised placebo controlled trial was conducted in men with limited mobility, over 65, living independently in the community. It was performed primarily to determine whether testosterone therapy led to increased muscle strength in this group.

However, the trial was discontinued early, after just 209 subjects had been enrolled, due to a significantly higher incidence of adverse cardiovascular events in the testosterone treated group (starting dose 10g 1% gel daily, adjusted to achieve a normal serum testosterone).